Partner Richard Manning has published an op-ed in the September 29 issue of The Hill. Dr. Manning drafted his article in response to another article in the Journal of the American Medical Association that examines the costs of bringing cancer medications to market and claims they are much lower than generally accepted estimates suggest. Dr. Manning explains how the study’s methodological flaws result in an inaccurate estimate of these costs. See above to read the article.
September 29, 2017